August 01, 2025 a 07:43 am
VRTX: Fundamental Ratio Analysis - Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals continues to present a stable outlook in the biotechnology sector, concentrating on cystic fibrosis and other rare conditions. Despite challenges in broader market dynamics, its strong product pipeline offers room for growth. Investors need to weigh its current valuation against future growth potential.
Fundamental Rating
Vertex Pharmaceuticals shows strong financial metrics yet illustrates certain weaknesses, hinting at moderate long-term growth potential.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical performance indicates consistent metrics with variations that reflect market conditions and operational efficacy.
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-31 | 2 | 4 | 1 | 1 | 3 | 1 | 1 |
| Previous | 0 | 4 | 1 | 1 | 3 | 1 | 1 |
Analyst Price Targets
Analysts remain optimistic about VRTX, predicting significant potential upside with room for volatility.
| High | Low | Median | Consensus |
|---|---|---|---|
| 535 | 420 | 442 | 465.67 |
Analyst Sentiment
There is a general favorability among analysts, with a majority rating Vertex a 'Buy'.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 39 | |
| Hold | 15 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Vertex Pharmaceuticals, though facing some financial headwinds, exhibits promising potential in its specialty markets. While it shows room for growth, investors should monitor its financial fundamentals closely. The broader biotechnology sector poses both opportunities and risks which are intrinsic to such investments. Overall, Vertex maintains a cautiously optimistic perspective from the analytical community. Careful consideration of macroeconomic factors should temper investment expectations.